Last reviewed · How we verify

Inflammatory biomarkers dosage "Normothermia Arm"

Centre Hospitalier Departemental Vendee · Phase 3 active Biologic

Inflammatory biomarkers dosage "Normothermia Arm" is a Biologic drug developed by Centre Hospitalier Departemental Vendee. It is currently in Phase 3 development for Measurement of inflammatory biomarkers in normothermic patients (likely post-cardiac arrest or critical illness).

This is a measurement protocol for inflammatory biomarkers under normothermic (normal body temperature) conditions, not a drug with a pharmacological mechanism.

This is a measurement protocol for inflammatory biomarkers under normothermic (normal body temperature) conditions, not a drug with a pharmacological mechanism. Used for Measurement of inflammatory biomarkers in normothermic patients (likely post-cardiac arrest or critical illness).

At a glance

Generic nameInflammatory biomarkers dosage "Normothermia Arm"
SponsorCentre Hospitalier Departemental Vendee
ModalityBiologic
Therapeutic areaCritical Care / Temperature Management
PhasePhase 3

Mechanism of action

This appears to be a clinical trial arm comparing inflammatory biomarker levels in patients maintained at normothermia (normal body temperature) versus other temperature management strategies. It is a diagnostic/monitoring protocol rather than a therapeutic agent with a defined mechanism of action.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Inflammatory biomarkers dosage "Normothermia Arm"

What is Inflammatory biomarkers dosage "Normothermia Arm"?

Inflammatory biomarkers dosage "Normothermia Arm" is a Biologic drug developed by Centre Hospitalier Departemental Vendee, indicated for Measurement of inflammatory biomarkers in normothermic patients (likely post-cardiac arrest or critical illness).

How does Inflammatory biomarkers dosage "Normothermia Arm" work?

This is a measurement protocol for inflammatory biomarkers under normothermic (normal body temperature) conditions, not a drug with a pharmacological mechanism.

What is Inflammatory biomarkers dosage "Normothermia Arm" used for?

Inflammatory biomarkers dosage "Normothermia Arm" is indicated for Measurement of inflammatory biomarkers in normothermic patients (likely post-cardiac arrest or critical illness).

Who makes Inflammatory biomarkers dosage "Normothermia Arm"?

Inflammatory biomarkers dosage "Normothermia Arm" is developed by Centre Hospitalier Departemental Vendee (see full Centre Hospitalier Departemental Vendee pipeline at /company/centre-hospitalier-departemental-vendee).

What development phase is Inflammatory biomarkers dosage "Normothermia Arm" in?

Inflammatory biomarkers dosage "Normothermia Arm" is in Phase 3.

Related